Skip to main content
PRE
NASDAQ Life Sciences

Prenetics Files Care Bears by IM8 License: 10-Year Term, GMRs, Royalties and ABG Equity Stake

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$16.2
Mkt Cap
$271.681M
52W Low
$11.365
52W High
$27.24
52W Position info
43% above low
Off High info
41% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PRE sits 43% above its 52-week low of $11.365.

Summary

Prenetics filed the actual Care Bears by IM8 license: a 10-year exclusive worldwide deal with Authentic Brands Group carrying guaranteed minimum royalties, a Net Sales royalty, Authentic equity in Prenetics, and a letter-of-credit backstop. Guidance excludes the brand entirely, so it is incremental — but the minimums are owed whether or not the products sell.


Key Events · M&A and Partnerships · PRE

  • 10-Year Exclusive Care Bears License Filed

    IM8 (US) LLC is exclusive worldwide operating partner for Care Bears vitamins, children's food and candy through December 31, 2036, with one 10-year renewal option; Prenetics records all Care Bears by IM8 revenue and pays Authentic a royalty.

  • Guaranteed Minimums Owed Every Contract Year

    The license sets a non-returnable Guaranteed Minimum Royalty for each of Contract Years 1-9 (2026-2036), recoupable against royalties earned in the same year and payable even if the products are never manufactured or sold. Exact dollar amounts are redacted in the exhibit.

  • Authentic Takes Prenetics Equity

    As additional consideration for Contract Years 2-9, Prenetics will issue Authentic shares of PRE common stock under a separate Share Subscription Agreement, vesting 100% each December 31 starting 2027. Share count and grant value are redacted.

  • Letter of Credit and Equity Covenant

    From Contract Year 2 Prenetics must post an irrevocable letter of credit for a stated percentage of that year's GMR, issued by a Hong Kong branch of a New York clearinghouse bank. Prenetics equity must also stay above a stated percentage of trailing four-quarter net sales; falling below is a non-curable breach allowing immediate termination.


Analysis · PRE · Life Sciences

The press release announced the partnership; this filing supplies the contract behind it. IM8 is exclusive worldwide operating partner for Care Bears wellness products through 2036, Prenetics books all Care Bears by IM8 revenue and pays Authentic a royalty plus a guaranteed minimum royalty every contract year — payable even if nothing sells. Authentic also takes Prenetics stock as part of the consideration, which ties the licensor to the share price and adds shares over time. The binding obligations are the part that matters: fixed annual minimums, a letter of credit securing them from Year 2, and an equity covenant that lets Authentic terminate outright if Prenetics' balance-sheet equity falls below a set level relative to trailing net sales. Management's 2026 and 2027 guidance excludes any Care Bears contribution, so the deal is pure upside to the current numbers — but it is also a multi-year cash commitment layered onto a company that is still scaling IM8.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRE was trading at $16.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $271.7M. The 52-week trading range was $11.37 to $27.24. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRE - Latest Insights

PRE
Nov 18, 2026, 12:40 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.17
Real-time Price: $10.76 info
Change: +$0.590 (+6%) info
Market Cap: $183.097M info
PRE
Nov 18, 2026, 8:06 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $17.83
Real-time Price: $10.76 info
Change: -$7.07 (-40%) info
Market Cap: $183.097M info
PRE
Nov 18, 2026, 8:05 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $17.83
Real-time Price: $10.76 info
Change: -$7.07 (-40%) info
Market Cap: $183.097M info
PRE
Nov 17, 2026, 10:35 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $16.09
Real-time Price: $10.76 info
Change: -$5.33 (-33%) info
Market Cap: $183.097M info
PRE
Nov 05, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $16.20
Real-time Price: $10.76 info
Change: -$5.44 (-34%) info
Market Cap: $183.097M info